---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-061465"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:41:07.515439+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# uniQure sells portion of HEMGENIX royalty rights for up to $400M cash; runway extended to Q2 2026

## Summary
- Receives $375M upfront from HealthCare Royalty and Sagard Healthcare for lowest royalty tier on HEMGENIX net sales.
- Eligible for $25M milestone if 2024 HEMGENIX net sales exceed pre-specified threshold.
- Purchaser's capped return up to 1.85x purchase price (2.25x if cap not met by 2032) through 2038.
- Retains rights to other royalties and future milestones from CSL Behring totaling up to $1.5B.
- Hercules loan amended: maturity extended to Jan 5, 2027; $1.25M fee; cash runway now into Q2 2026.

## SEC filing metadata
- accession: 0001104659-23-061465
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465923061465/0001104659-23-061465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465923061465/tm2315929d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-061465
- JSON: https://secwatch.observer/filing/0001104659-23-061465.json
- Plain text: https://secwatch.observer/filing/0001104659-23-061465.txt

## Key facts
- Debt Financings
  uniQure N.V. entered an off-balance-sheet arrangement for debt of $375 million with HemB SPV, L.P. maturing June 30, 2032.
  - Principal: $375 million
  - Counterparty: HemB SPV, L.P.
  - Maturity: June 30, 2032
  - Event: off balance sheet
  source text: ith HemB SPV, L.P. (“Purchaser”) for the sale of a portion of the royalty rights due to the Company from CSL Behring LLC
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465923061465/0001104659-23-061465-index.htm
- Debt Financings
  uniQure N.V. amended credit facility with Hercules Capital, Inc. maturing January 5, 2027.
  - Instrument: credit facility
  - Counterparty: Hercules Capital, Inc.
  - Maturity: January 5, 2027
  - Event: amendment
  source text: Additionally, the maturity date and the interest-only period of the Loan Agreement was extended to January 5, 2027.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465923061465/0001104659-23-061465-index.htm
- Material Agreements
  uniQure N.V. entered into Royalty Purchase Agreement with HemB SPV, L.P. valued at Upfront cash payment of $375 million, plus potential $25 million milestone payment (effective 2023-05-12).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: HemB SPV, L.P.
  - Value: Upfront cash payment of $375 million, plus potential $25 million milestone payment
  - Effective: 2023-05-12
  source text: On May 12, 2023, uniQure biopharma BV, a wholly-owned subsidiary of uniQure N.V., (the “Company”) entered into a royalty purchase agreement (the “Purchase Agreement”) with HemB SPV, L.P. (“Purchaser”) for the sale of a portion of the royalty rights due to the Company from CSL Behring LLC (“CSL Behring”) under the commercialization and license agreement between the Company and CSL Behring dated as of June 24, 2020 (the “Commercialization and License Agreement”), from the net sales of HEMGENIX® (the “Product”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465923061465/0001104659-23-061465-index.htm
- Material Agreements
  uniQure N.V. amended Amendment No. 1 to Third Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. valued at Extension of maturity date and interest-only period to January 5, 2027, and $1.25 million fee payabl (effective 2023-05-12).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Hercules Capital, Inc.
  - Value: Extension of maturity date and interest-only period to January 5, 2027, and $1.25 million fee payabl
  - Effective: 2023-05-12
  source text: In connection with the execution of the Purchase Agreement, the Company entered into Amendment No. 1 (the “Amendment”) to the Third Amended and Restated Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”) in its capacity as administrative agent and collateral agent for itself and the other financial institutions or entities party thereto as lenders (the “Lenders”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465923061465/0001104659-23-061465-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.